Stefan C. Weiss, MD, MBA, is now the Chief Medical Officer at SFA Therapeutics, Inc. a clinical-stage biopharmaceutical company developing oral small-molecule biosynthetic compounds for the treatment of inflammatory diseases. SFA’s lead asset, SFA-002, is approaching Phase 2 clinical trials and has shown promising Phase 1a and Phase 1b results for the treatment of psoriasis.
Most recently, Dr. Weiss was the Managing Director of Dermatology at OM1, a company focused on health care data analytics and artificial intelligence. He received his undergraduate degree with honors from Yale University in New Haven, CT, his MD and MSc in clinical research from the Duke University School of Medicine in Durham, NC, and his MBA from the Kellogg School of Management at Northwestern University in Chicago. He completed a residency in Dermatology at Stanford University in Stanford, CA, and a Fellowship in Bioethics at the National Institute of Health.
“Dr. Weiss brings decades of multi-faceted clinical and industry experience in both dermatology and immunology,” says Ira Spector, PhD, CEO of SFA Therapeutics, in a news release. “His expertise in dermatologic therapeutic development will be indispensable for the company as we advance SFA-002 in clinical trials for the treatment of psoriasis. Dr. Weiss will also advise us on the best course of action for leveraging our platform to develop additional therapeutic candidates for other indications.”
“I am honored to join the SFA Therapeutics team to help shape the clinical pathway forward for SFA-002 and other candidates that target inflammatory disease. As a practicing dermatologist, I have witnessed the immense need for novel therapeutics with greater efficacy and fewer side effects than the currently available treatments for chronic inflammatory skin conditions,” adds Dr. Weiss, Chief Medical Officer of SFA Therapeutics. “I am confident in SFA Therapeutics’ novel approach which acts on multiple therapeutic pathways by using endogenous biosynthetic compounds. SFA Therapeutics is well-positioned to provide potentially safer and more efficacious treatments for chronic inflammatory diseases like psoriasis.”
